Treatment options for depression and psychosis in Parkinson's disease

Journal of Neurology, Supplement

Volumn 248, Issue 3, 2001, Pages 12-21

  Poewe, W ^a   Seppi, K ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Depression; Parkinson's disease; Psychosis; Treatment options

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; IMIPRAMINE; LEVODOPA; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PRAMIPEXOLE; REBOXETINE; SELEGILINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AFFECTIVE NEUROSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DEMENTIA; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; ELECTROCONVULSIVE THERAPY; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE;

EID: 0034788540     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00007821     Document Type: Conference Paper

References (133)

1. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia
2. Antidepressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA
3. Parkinson's disease, depression, and ECT: A review and case study
4. Electroconvulsive therapy in parkinsonism with affective disorder
5. Worsening of psychotic symptoms by clozapine in Parkinson's disease
6. Olanzapine-induced neutropenia after clozapine-induced neutropenia
7. Clozapine in idiopathic Parkinson's disease
8. Electroconvulsive therapy in the treatment of combined depression and Parkinson's disease
9. Does fluoxetine exacerbate Parkinson's disease?
10. Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms
11. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease
12. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
13. Depression and Parkinson's disease: A review
14. Neuropsychiatric complications of drug treatment of Parkinson's disease
15. Psychiatric aspects in parkin-sonism treated with L-dopa
16. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease
17. ECT and Parkinson's disease revisited: A "naturalistic" study
18. Levodopa-induced dyskinesias are improved by fluoxetine
19. Improvement of depression and parkinsonism during ECT: A case study
20. Clozapine-induced acute interstitial nephritis
21. Clozapine prevents recurrence of psychosis in Parkinson's disease
22. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial
23. Parkinson's disease: Drug-induced psychiatric states
24. Parkinson's disease: Follow-up after "drug holiday"
25. Quetiapine for l-dopa-induced psychosis in PD
26. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
27. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
28. ECT-induced delirium in depressed patients with Parkinson's disease
29. Dopaminergic psychosis in advanced Parkinson's disease
30. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
31. The management of the levodopa psychoses
32. Management of psychosis in Parkinson's disease
33. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
34. Substituting clozapine for olan-zapine in psychiatrically stable Parkin-son's disease patients: Results of an open label pilot study
35. Clozapine in the treatment of psychosis in Parkinson's disease
36. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
37. Risk factors for nursing home placement in advanced Parkinson's disease
38. The use of clozapine in Parkinson's disease
39. Depression in Parkinson's disease: A quantitative and qualitative analysis
40. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: A cautionary note
41. Clozapine therapeutic plunge in patient with Parkinson's disease
42. Treatment of drug-induced psychosis in Parkinson's disease with clozapine
43. Association of venous thromboembolism and clozapine
44. Sertraline for the treatment of depression in Parkinson's disease
45. Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems
46. Imbalance of brain monoamines and clinical disorders
47. Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease
48. Is the mesocortical dopaminergic system involved in Parkinson disease?
49. Olanzapine can worsen parkinsonism
50. Parkinsonism exacerbated by paroxetine
51. Antiparkinsonian and antide-pressant effects of high doses of bromocriptine. An independent comparison
52. Clozapine is beneficial for psychosis in Parkinson's disease
53. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
54. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression
55. Myocarditis and cardiomyopathy associated with clozapine
56. Psychiatric side effects during the treatment of Parkinson's disease
57. Are levodopa "holidays" justified?
58. Complications of chronic levodopa therapy: Long-term efficacy of drug holiday
59. Neuroleptic malignant syndrome
60. Depression and Parkinson's disease: Possible role of serotonergic mechanisms
61. Desipramine in treatment of Parkinson's disease. A placebo-controlled study
62. Improvement of parkinsonism in depressed patients treated with ECT
63. Deprenyl in Parkinson's disease
64. Parkinsonism: Improvement by electroconvulsive therapy
65. Clozapine treatment of parkinsonism with psychosis
66. Treatment of parkinson's disease with bromocriptine
67. Deprenyl versus placebo in Parkinson disease: A double-blind study
68. Letter: Electroconvulsive therapy in patients with parkinsonism
69. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor
70. Low-dose olanzapine for levodopa induced dyskinesias
71. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study
72. Does levodopa alter depression and psychopathology in parkinsonism patients?
73. Depression in the patient with Parkinson's disease
74. The mental status in Parkinson's disease
75. Altered serotonin metabolism in depressed patients with parkinson's disease
76. Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease
77. Clinical and biochemical features of depression in Parkinson's disease
78. Serotonergic dysfunction in depression associated with Parkinson's disease
79. Sertraline for the treatment of depression in Parkinson's disease
80. Treatment of hypokinetic rigid syndrome with fluvoxamine maleate
81. Reversible leucopenia related to olanzapine
82. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine
83. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease
84. Effectiveness of ECT in patients with parkinsonism
85. Worsening of motor features of parkinsonism with olanzapine
86. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study
87. Olanzapine-induced agranulocytosis
88. The neurobiology of ECT: Animal studies
89. Cognitive impairment after ECT in patients with Parkinson's disease and psychiatric illness
90. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
91. Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease
92. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: Three year interim report
93. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease
94. Clozapine for psychosis in Parkinson's disease
95. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease
96. Evidence-based medicine review of PD treatments: The MDS project
97. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease
98. Letter: Parkinsonism masked by ECT and psychotropic medication
99. Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
100. A survey of antidepressant drug use in Parkinson's disease
101. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease
102. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series
103. Cabergoline in the treatment of early Parkinson's disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa
104. Retrospective study of selegiline-antide-pressant drug interactions and a review of the literature
105. Clozapine treatment of psychosis in Parkinson's disease
106. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease
107. Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis
108. Monoaminergic actions of ECT
109. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease
110. Electroconvulsive therapy
111. Coexisting dementia and depression in Parkinson's disease
112. Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism
113. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine
114. Increase of Parkinson disability after fluoxetine medication
115. Moclobemide and selegeline in the treatment of depression in Parkinson's disease
116. Imipramine in treatment of Parkinson's disease: A double-blind placebo study
117. The occurrence of depression in Parkinson's disease. A community-based study
118. Efficacy of quetiapine in Parkinson's patients with psychosis
119. Tolerability of paroxetine in Parkinson's disease: A prospective study
120. Clozapine in drug-induced psychosis in Parkinson's disease
121. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
122. Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa
123. Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience
124. Deprenyl in Parkinson's disease: Mechanisms, neuroprotective effect, indications and adverse effects
125. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients
126. Clozapine for the treatment of psychosis in Parkinson's disease: Chart review of 49 patients
127. Electroconvulsive therapy in parkinsonian patients with the "on-off" syndrome
128. Quetiapine for l-dopa-induced psychosis in PD
129. Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: Retrospective review
130. Letter: Parkinsonism, depression, and ECT
131. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
132. Dissociation of motor response from mood and cognition in a parkinsonian patient treated with ECT
133. Parkinson's disease, depression, and electroconvul-sive therapy: A clinical and neurobiologic synthesis